# Meglumine antimoniate

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.2. Antileishmaniasis medicines

EMLc | ATC codes: P01CB01

| | |
|---|---|
| **Indication** | Visceral leishmaniasis ICD11 code: 1F54.0 |
| **Medicine type** | Chemical agent |
| **List type** | Core |
| **Formulations** | **Parenteral > General injections > IM:** 1.5 g per 5 mL in 5 mL ampoule |
| **EML status history** | First added in 1987 (TRS 770)<br>Changed in 1989 (TRS 796)<br>Changed in 2002 (TRS 914)<br>Changed in 2007 (TRS 950)<br>Changed in 2009 (TRS 958)<br>Changed in 2023 (TRS 1049) |
| **Sex** | All |
| **Age** | Also recommended for children |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Wikipedia** | Meglumine antimoniate |
| **DrugBank** | Meglumine antimoniate (Pentavalent Antimony) |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule